Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails
12:05pm, Friday, 26'th May 2023
Apellis' (APLS) phase II MERIDIAN study on pegcetacoplan for the treatment of amyotrophic lateral sclerosis fails to meet primary and key secondary endpoints.
Why These 3 Nasdaq Stocks Buckled Today
03:42pm, Tuesday, 16'th May 2023
The Federal Trade Commission is suing to block the proposed merger between Amgen and Horizon Therapeutics. This adverse regulatory action rippled out across the small- and mid-cap biotech landscape to
Apellis Pharmaceuticals, Inc. (APLS) Q1 2023 Earnings Call Transcript
10:56am, Saturday, 06'th May 2023
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Meredith Kaya - Senior Vice President, Investor Relations and Strategic Financ
Apellis (APLS) Q1 Earnings Miss, Empaveli & Syfovre Fuel Growth
10:40am, Friday, 05'th May 2023
Apellis Pharmaceuticals' (APLS) loss in the first quarter is wider than estimates. Empaveli and Syfovre boost product revenues for the company.
Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views
09:36am, Friday, 05'th May 2023
Apellis' new eye drug, Syfovre, crushed expectations in its first quarter post launch, putting APLS stock on track to open at a record high. The post Top-Notch Biotech Apellis Soars After New Drug Obl
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
07:01pm, Thursday, 04'th May 2023
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $1.42. This compares to loss of $1.42 per share a year ago.
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
07:00am, Wednesday, 03'rd May 2023
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will pres
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
04:28pm, Monday, 01'st May 2023
Biotech stocks were fairly volatile today, thanks to another buyout and a spate of earnings reports. Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics were among the most volatile in t
Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
07:00am, Thursday, 27'th Apr 2023
WALTHAM, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ho
These Are the Top 10 Holdings of Avoro Capital Advisors
10:54pm, Monday, 17'th Apr 2023
Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.
Apellis (APLS) Stock Up 50% in Three Months: Here's Why?
12:16pm, Tuesday, 11'th Apr 2023
Apellis (APLS) stock rises 50% in the past three months owing to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake in its first marketed product, Empaveli, also cont
Strength Seen in Apellis Pharmaceuticals, Inc. (APLS): Can Its 16.3% Jump Turn into More Strength?
05:21am, Tuesday, 04'th Apr 2023
Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further
2 Best Growth Stocks to Buy in April
10:00am, Monday, 03'rd Apr 2023
Growth stocks have been under heavy pressure over the past year. A handful of biotech companies have defied this broader downturn, however.
Apellis (APLS) Kindles Acquisition Interest Per Bloomberg
09:07am, Monday, 03'rd Apr 2023
Per a Bloomberg article, Apellis Pharmaceuticals (APLS) is considering a possible buyout by larger pharma companies.
Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 7% Since Last Earnings Report?
12:59pm, Thursday, 23'rd Mar 2023
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?
